Idera Pharmaceuticals, Inc announced the issuance of patents covering its novel immune modulatory oligonucleotides (IMO), chemical modifications of IMOs, and methods of inducing an immune response through administering such compounds.

The issued patents include: US 7,427,405, entitled 'Immunostimulatory Oligonucleotide Multimers', 'US 7,407,944, entitled 'Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends', US 7,405,285, entitled 'Immunostimulatory Oligonucleotide Multimers' and AU 2006203435, entitled 'Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs by Positional Chemical Changes'.

"The claims of the recently issued patents cover novel compounds and methods of using these compounds, including our lead candidate for infectious disease, IMO-2125," said Steven Ritter, vice president of Intellectual Property and Contracts. "We continue to expand the patent portfolio covering our synthetic, DNA-based Toll-like Receptor (TLR)-targeted compounds, which are created through our chemistry-based drug discovery approach to TLR-targeted therapy."

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants.